Little or no data are available on the immunotoxicity of the new deoxycytid
ine analogue, gemcitabine (2'-2'-Difluorodeoxycytidine, dFdC). The drug was
tested on natural killer (NK), interleukin 2-activated killer (LAK) and an
tigen-dependent cytotoxic effector cells (CTL) activity. NK cells were trea
ted for 16 hours and then tested against K562 cell line. LAK cells were pre
treated for 16 hours before or after IL2 stimulation, and tested against DA
UDI cells on day 4. CTL were pretreated for 16 hours on day -1 or on day 4
of coculture, and then tested against MT-2 on day 5. Cytotoxic activity was
evaluated by a 4 Cr-51-release assay. The results indicate that dFdC inhib
its hours markedly LAK or CTL generation, but does so less efficiently on "
mature" LAK or CTL lymphocyte function and only slightly on NK cell activit
y. Therefore dFdC cart be considered immunotoxic for either natural or anti
gen-dependent cell-mediated immunity.